ALLOGENE THERAPEUTICS

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

13 May 2025 13:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

06 May 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 07:12:13 By Nasdaq GlobeNewswire

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

07 Apr 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

13 Mar 2025 13:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

03 Mar 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in March Investor Conference

26 Feb 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

25 Feb 2025 13:10:07 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

13 Feb 2025 13:30:30 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in February Investor Conferences

04 Feb 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

29 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

28 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

16 Dec 2024 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

12 Dec 2024 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in December Investor Conferences

19 Nov 2024 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

18 Nov 2024 05:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

07 Nov 2024 13:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

07 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

05 Nov 2024 06:10:30 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in November Investor Conferences

04 Nov 2024 05:30:00 By Nasdaq GlobeNewswire